Royalty Pharma plc (RPRX) Stock: What Does the Chart Say Tuesday?

Overall market sentiment has been down on Royalty Pharma plc (RPRX) stock lately. RPRX receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Royalty Pharma plc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on RPRX!

See Full RPRX Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With RPRX Stock Today?

Royalty Pharma plc (RPRX) stock is higher by 7.76% while the S&P 500 has fallen -0.05% as of 2:21 PM on Tuesday, Feb 6. RPRX has risen $2.15 from the previous closing price of $27.71 on volume of 3,509,046 shares. Over the past year the S&P 500 has risen 20.17% while RPRX has fallen -21.98%. RPRX earned $0.40 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 75.25. To screen for more stocks like Royalty Pharma plc click here.

More About Royalty Pharma plc

Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates. Click Here to get the full Stock Report for Royalty Pharma plc stock.